Loading stock data…
908 Devices Inc. (MASS)
$9.81-0.24 (-2.39%)
Market ClosedLast close Sep 8
908 Devices Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
908 Devices Inc. in the Healthcare sector is trading at $9.81 with a market capitalization of $405M. Wall Street consensus targets $13.00 (3 analysts), implying a +32.5% move over the next 12 months. The stock is currently 13% below its 52-week high of $11.25, remaining 34.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +32.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $13.38M↓ | $17.38M↑ | $14.01M↑ | $13.04M↑ | $11.78M |
| Gross Profit | $6.88M↓ | $9.15M↑ | $7.36M↑ | $6.37M↑ | $5.54M |
| Operating Income | -$6.50M↓ | -$3.17M↑ | -$5.62M↑ | -$8.37M↑ | -$8.53M |
| Net Income | -$11.96M↓ | $4.17M↑ | -$14.98M↓ | -$13.31M↓ | $43.60M |
Peer Comparison
JNJUNHPFE
Fundamentals
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company's products include MX908, a handheld, battery-powered, and Mass Spec device ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$405.48M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.68
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.34%
Volume
Today's trading volume
241,573
Recent News
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices (NASDAQ:MASS) outlined its strategy to expand in handheld chemical detection following second-quarter 2026 results that showed revenue growth, a narrower adjusted EBITDA loss and increasing recurring revenue. Speaking at the Midwest IDEAS Conference, CEO and Co-Founder Kevin Knopp said
908 Devices (MASS) Q2 2026 Earnings Call Transcript
Revenue grew 23% to $16.1 million as adjusted EBITDA loss improved 50%.
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago. Speaking at a Canaccord Genuity event, President, CEO and Co-Founder K
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
908 Devices (NASDAQ:MASS) is sharpening its focus on handheld chemical and drug detection systems for public safety, defense and law enforcement following the divestiture of its bioprocessing and biopharma business line, executives said during a Canaccord Genuity discussion. Chief Executive Officer
908 Devices Inc (MASS) (Q2 2026) Earnings Call Highlights: Strong Revenue Growth and Raised ...
908 Devices Inc (MASS) delivered 23% revenue growth in Q2 2026, driven by robust demand and strategic acquisitions, while improving profitability and raising full-year guidance.